Biomeditsina va amaliyot jurnali, 2022 №1
Subject of the article
THE MAIN DIRECTIONS OF RESEARCH IN THE FIELD OF CELLULAR TECHNOLOGIES AND THE ROLE OF STEM CELL BANKS IN MODERN MEDICINE IN RUSSIA (89-99)
Authors
ADILOV Sherzod Ubaydullaeva Zuxra
Institution
Research and production enterprise «Blood products» of the Main Directorate of Health, Tashkent “Stem cell bank Pokrovsky”, Ltd, St. Petersburg, Russia
Abstract
The world market of biotechnology for the preparation and reception of umbilical cord blood cells is constantly evolving. In Russia, the market for umbilical cord blood cells is also slowly developing, and the market for biotechnological services is beginning to take its place. In Russia, a bank of registered and licensed umbilical cord blood cells can aim to occupy 5-10% of this market, which provides 1,500 to 3,000 umbilical cord samples per year for each enterprise. The volume of the collected umbilical cord blood sample is very small and is then stored in a special vascular cell bank for use by a specific person. The umbilical cord cells are still grown in a laboratory with limited capacity. The limited amount of cell material in a single sample often does not allow it to be used for transplantation in an elderly patient, so it is necessary to resort to the cultivation of umbilical cord blood cells. The disadvantages of working with mesenchymal vascular cells and hematopoietic vascular cells are: difficulty in separating them from adult tissue, high cost of isolation and high cost of extraction (ex vivo). Cultivation of these cells allows them to be obtained in large quantities for research purposes (for the development of new drugs and, in particular, for toxicological screening) and for transplantation to patients in regenerative medicine. The main feature of embryonic vascular cells is their pluripotent nature, ie the ability to differentiate into a wide range of cells in the human body.
Key words
stem cells, cell therapy, umbilical cord blood.
Literature
1. Смолянинов А.Б., Хурцилава О.Г., Жаров Е.В., Кованько Г.М. Роль регистра доноров костного мозга и банков пуповинной крови в современной медицине // АГ$инфо (Информационный журнал по акушерству и генекологии). – № 4, 2007. – С.14–16. 2. Смолянинов А.Б., Жаров Е.В., Мовчан К.Н. и соавт. Клеточные и генные технологии в трансплантационной тканевой инженерии // АГинфо (Информационный журнал по акушерству и генекологии). – № 4, 2008. – С.11–19. 3. Смолянинов А.Б., Обрезан А.Г., Адылов Ш.Ф. Гемопоэтические стволовые клетки и преимущества трансплантации пуповинной крови // Медицина XXI век (научно- практический журнал).– № 3 (12), 2008. – С.20–22. 4. Broxmeyer H.E. Cord blood: biology, immunology, banking, and clinical transplantation // AABB Press, Bethesda, Maryland. – 2004. – 455 p. 5. Broxmeyer H.E., Kurtzberg J., Glucman E. et al. Umbilical cord blood hematopoietic stem and repopulating cells in human clinical transplantation // Blood cell. – 2004, № 17. – P.313–29. 6. Glucman E., Broxmeyer H.E., Auerbach A.D. et al. Hematopoietic reconstitution in a patient with Fanconi anemia by means of umbilical – cord blood from an HLAidenticalsibling // N. Engl. J. Med. –1989, № 321. – P.1174–8. 7. Kohli, Kumar M., Shahidi N.T., Broxmeyer H.E. et al. Hematopoietic stem/progenitor cell trasplantat in Fanconi anemia using HLAmatched sibling umbilical cord blood cell // Br. J. Haematol. – 2005, № 85. – P.419–22. 8. Stem cell. Cell therapy markets (Trends, industry participants,product overviews and market drivers // TriMark Publications. –2007. – 270 p. 9. Smolyaninov A., Savintsev A., Khutrsilava O. et al. Clinical use mononuclear fraction of autologous bone marrows in the treatment of closed fractures of long tubular bones // EurAsian Journal of BioMedicine. – Vol.1, № 8. – 2008. – P.14–19. 10. Wagner J.E., Broxmeyer H.E., Byrd R.L. et al. Transplantation of umbilical cord blood after myeloblative therapy: Analysis of engraftment // Blood. – 1998, № 79. – P.1874–81. 11. Wagner J.E., Kernan N.A., Steinbuch M. et al. Allogenic sibling umbilical cord blood transplantation in forty-four children with malignant and non$malignant disease // Lancet. – 1996, № 346. –P.214–9. 12. Macmillan M.L., Blazar B.R., DeFor T.E. & Wagner, J.E. Transplantation of ex vivo culture expanded parental haploidic tical mesenchymal stem cells to promote engraftment in pediatric recipients of unre lated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplantation, 2009, 43, 447–454. 13. De Lima M., McMannis J., Gee et. al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplantation, 2008, 41, 771–778. 14. Locatelli F., Maccario R. Frassoni F. Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immunemediated disorders? Haematologica, 2007, 92, 872–877. 15. Rocha V. & Locatelli, F. Searching for alternative donors of haematopoietic stem cell for paediatric patients. Bone Marrow Transplantation, 2008, 41, 207–214. 16. Macmillan M.L., Weisdorf D.J., Brunstein C.G., Cao Q., et. al. Acute graft versus host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood, 2009, 113, 2410–2415. 17. Frassoni F., Gualandi F., Podesti M., et. al. Direct intrabone transplant of unrelated cord blood cells in acute leukemia: a phase I/II study. Lancet Oncology, 2008, 9, 831–839. 18. Bautista G., Cabrera J.R., Regidor C., et. al. Cord blood transplants supported by co infusion of mobilized hematopoietic stem cells from a third party donor. Bone Marrow Transplantation, 2009, 43, 365–373.